Clinical Trials

The James Cancer Center Columbus, OH

open for enrollment

Ph III Sacituzumab Govitecan vs Physician Choice w/ Metastatic Triple-Negative

Protocol: OSU-18002

Full Title

An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments

Breast Cancer